What are the major and minor symptoms of infection with the new subtype of Omicron? What do experts think about the role it will play in the evolution of the pandemic?
"The war that exists, the perpetual war between man and the microcosm of microbes and viruses, seems to have no end. [...] Mutations are the weapons that microbes and viruses have to be able to escape human pressure," said in early 2021 the Emeritus Professor of Pediatrics and President of the National Vaccination Committee, Maria Theodoridou, on the occasion of the B117 strain of the Alpha variant, better known as the "British mutation".
A year and a half later, the SARS-CoV-2 coronavirus quiver seems inexhaustible and, from the Delta and Omicron mutants to the recent BA.4 and BA.5 responsible for the resurgence of the epidemic today, the virus introduces to humanity the 'Centaurus' mutation. In particular, this is the new Omicron sub-variant with the scientific name BA.2.75 which was first detected in India last May and now cases have been reported in at least 10 additional countries, including the UK, USA, Australia, Germany, Japan and Canada.
Suspicious symptoms
The landscape is still murky regarding the Centaurus sub-variant, given its recent spread in the population and the still incomplete data. As with its infectivity and morbidity, scientists are relying on early observations for the symptoms that accompany infection with this strain. According to these, symptoms are similar to those of other Omicron subtypes and include:
- cough
- fever
- fatigue or weakness
- headache
- nasal congestion and/or runny nose
- other respiratory manifestations suggestive of a cold or flu.
- Sore throat mainly followed by diarrhoea, dyspnoea, vomiting and muscle aches are some minor symptoms that have been associated with disease from the Omicron variant and its sub-variants, while there is little chance of anosmia and agueusia, predominant symptoms of COVID-19 disease in the early waves of the pandemic.
It should be noted that due to the shorter incubation period of Omicron and its sub-variants, it is estimated that symptoms occur more rapidly after infection.
Preliminary scientific assessments
There is currently no consensus within the scientific community on the potential for the new Centaur sub-variant to prevail over BA.4 strains. and BA.5 and trigger a new pandemic wave. Some scientists link its emergence to an increase in cases, as is the case in the United Kingdom and the United States, and predict a more rapid spread due to more mutations in the spike protein compared to strains BA.2, BA.4, BA.5 and other SARS-CoV-2 mutations.
The European Centre for Disease Prevention and Control (ECDC) described it on 7 July as a "variant under surveillance", meaning it carries indications that it could be more contagious or associated with more severe disease, which cannot yet be assessed. The World Health Organization (WHO) also follows a similar line, announcing that it is monitoring it closely and is waiting for more data to assess its severity.
Statements about the "Centaurus" strain were made on SKAI television by the Assistant Professor of Epidemiology and member of the Committee of Experts, Mr. Gikas Majorkinis, stating, among other things, that there is no outbreak or wave of the new sub-variant observed so far, despite its dispersion, therefore they are monitoring its spread.
Less optimistic estimates were expressed via his personal Facebook account by Professor of Pulmonology at the Medical School of the University of Crete, Mr. Nikos Tzanakis, speaking of a problematic surprise from the coronavirus that he expected to occur by September and that "things do not look good". In his post he states: "This evolution of the virus, with a strong affinity to Omicron 2, will probably plague us again since it is probably more contagious than Omicron 5. More importantly, the lightning developments with the mutant strains are putting the strategic response to the pandemic so far to the test. Might key aspects of the current strategy need to be revised? Is it right to draw parallels between this pandemic and known pandemics to date and to use the same response measures? Should our strategy be enriched with new innovative response measures that technology and science are already promoting? Let us remain optimistic and incurably supportive of science.
Concerning the morbidity of the new sub-variant, some scientists appear reassuring, citing the milder disease characterising the Omicron variant in general and, finally, leaving little room for adequate protection by the available vaccines, although on 6 July the WHO recommended vaccination - initial or booster - for high-risk groups, i.e. the elderly, people with chronic diseases, immunocompromised people and health workers.
Source: ygeiamou.gr
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source